SHASUN CHEMICALS & DRUGS: DIVERSIFICATION IS THE KEY

Article Abstract:

Shasun Chemicals & Drugs (SC&D) of Chennai is engaged in the manufacture of ibuprofen, ranitidine and intermediaries. It has increased the capacity of its ranitidine facility from 240 tonnes per annum (tpa) to 360 tpa. Its ibuprofen capacity is 3,000 tpa. --------------------------------------------------------- Financial performance of Shasun Chemicals & Drugs --------------------------------------------------------- Particulars 1996-97 1995-96 (Rs in crore) --------------------------------------------------------- Sales 123.06 84.28 --------------------------------------------------------- Operating profit 17.66 10.33 --------------------------------------------------------- Interest 8.08 2.54 --------------------------------------------------------- Depreciation 2.55 1.63 --------------------------------------------------------- Tax 0.90 - --------------------------------------------------------- Net profit 6.13 6.16 --------------------------------------------------------- Equity 8.22 8.22 --------------------------------------------------------- EPS (Rs) 7.46 7.49 --------------------------------------------------------- Dividend (%) 25.00 25.00 --------------------------------------------------------- It is launching 2 more products - Naproxen and Nizatidine. It is setting up a 60 tpa capacity which is likely to start production in 1998-99. It plans to produce 2,800 tonnes of ibuprofen in 1998 and export 1,500 tonnes of it. Its exports of ranitidine and intermediates are projected at 150 tonnes, worth Rs80 crore. It completed its expansion of its facilities at Cuddalore and Pondicherry. Its scrip is trading at Rs25 at a price earning multiple of 14. (rk)

Comment:

Posts a decrease in its net profit to Rs6.13 crore in 1996-97 from Rs6.16 crore in 1995-96

Ibuprofen Pain Relievers, Ibuprofen, Article, Shasun Chemicals and Drugs

---

CORE HEALTHCARE

Article Abstract:

Core Healthcare Ltd has a debt-equity ratio of 3:1, which would be 4:1 if its accumulated losses of Rs147.77 crore are taken into account. Its turnover was Rs265.17 crore in 1997-98. Its net loss was Rs96.23 crore. It is seeking the help of financial institutions for restructuring itself from January 1998. It is seeking re-fixation of loan repayment schedule from 2000 AD and reduction of interest rate from 21 percent to 19 percent. In the first quarter of 1998-99, it incurred a loss of Rs21.60 crore on a turnover of Rs85.81 crore. Its scrip is trading at Rs9.95. (tsm) (kvr)

Comment:

Core Healthcare Ltd has a debt-equity ratio of 3:1, which would be 4:1 if its accumulated losses of Rs147.77 crore are taken into account.

Vitamin, Nutrient & Hematinic Preps, Core Healthcare Ltd.

---

AUROBINDO PHARMA

Article Abstract:

Aurobindo Pharma (AP) of Hyderabad produces drugs. Its Amoxycillin is the largest prescribed anti-biotic in India. AP has reduced its raw material imports from 60 percent to 46 percent. It has announced a dividend of 50 percent for 1997-98. Its scrip is now trading at Rs315. (uh)

Production management, Systemic Antibiotic Preparations, Antibiotics, Aurobindo Pharma

Similar abstracts:

• Abstracts: TATA CHEMICALS NAGARJUNA FERTILIZERS AND CHEMICALS LIMITED. SWC BOARD RECAST, KOMAL WAZIR MADE DIRECTOR
• Abstracts: LUPIN LABORATORIES LTD DHARAMSI MORARJI CHEMICALS: CORE COMPETENCIES?
• Abstracts: COMPUTECH INTERNATIONAL LIMITED: BRINGING YOU THE FUTURE... TODAY COMPUTECH INTERNATIONAL: OPTIMISTIC APPROACH
• Abstracts: STATE BANK OF INDIA: VENTURING INTO NEW AREAS BANK OF INDIA GLOBAL TRUST BANK: BRIGHT OUTLOOK

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.